Two-Part Webinar Series: Federal Funding and Contracting Opportunities for Life Sciences Companies
The DoD awards over a billion dollars annually to life sciences companies to support the development and manufacturing of medical products. Join this two-part series to learn how to win and perform DoD contracts.
Part One: There's More to U.S. Government Procurement Than the FSS
July 12 | 12-1 p.m. EDT
Many life sciences companies are familiar with selling products and services to the U.S. government through the VA's Federal Supply Schedule (FSS) program or the DoD's Medical-Surgical Prime Vendor program. But both seasoned federal contractors and newer entrants to the space alike may not realize the breadth and depth of federal funding and contracting opportunities available to support asset development and other corporate initiatives.
Over the past decade, the U.S. government has exponentially increased its investment in the development, manufacture, and commercialization of new therapies, diagnostics, and other medical supplies and services for a range of conditions. The DoD, HHS, and other federal agencies awarded nearly US$179.5 billion to industry in FY21 alone to support these and other areas of strategic national importance identified by the U.S. government. While this amount was boosted by COVID-19 spend, there is every indication this trend will continue post-pandemic.
So, then, how can life sciences companies enter the fray? This first webinar lays the groundwork. It will:
- Provide an overview of the federal funding landscape post-COVID-19, including key agencies and contracting mechanisms
- Discuss the DoD's organization of its life sciences funding opportunities and how to compete for these opportunities throughout a product's and/or company's life cycle
- Introduce a range of compliance, intellectual property, and other nuanced obligations and considerations that may impact life sciences companies that bid for federal support or decide to pursue potential opportunities
Part Two: Rewarding but Potentially Risky — Considerations When Bidding for and Performing DoD Contracts
July 13 | 12-1 p.m. EDT
DoD is one of the U.S. government's largest federal agency sponsors of biomedical research, awarding billions of dollars annually to life sciences companies to support the development of new drugs, vaccines, medical devices, and many other products and services. But this federal funding comes with significant strings attached and can potentially pose substantial compliance, enforcement, business, and other risks — some obvious, but others less so.
This second webinar will cover:
- Mandatory disclosures, requirements, and assertions, and what's potentially negotiable
- Rules controlling IP developed with government funding (e.g., "march-in" rights), and ways to protect these valuable assets
- Domestic production and country of origin requirements
- Pricing issues
- Common compliance and enforcement risks and related mitigation strategies